Fragment-based discovery of type i inhibitors of maternal embryonic leucine zipper kinase

ACS Medicinal Chemistry Letters

Volumn 6, Issue 1, 2015, Pages 25-30

  Johnson, Christopher N ^a   Berdini, Valerio ^a   Beke, Lijs ^b   Bonnet, Pascal ^b,c   Brehmer, Dirk ^b   Coyle, Joseph E ^a   Day, Phillip J ^a   Frederickson, Martyn ^a   Freyne, Eddy J E ^b   Gilissen, Ron A H J ^b   Hamlett, Christopher C F ^a   Howard, Steven ^a   Meerpoel, Lieven ^b   McMenamin, Rachel ^a   Patel, Sahil ^a   Rees, David C ^a   Sharff, Andrew ^a   Sommen, François ^b   Wu, Tongfei ^b   Linders, Joannes T M ^b  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Université d'Orléans   (France)

Author keywords

fragment based drug design; Maternal embryonic leucine zipper kinase; structure based optimization

Indexed keywords

FLT3 LIGAND; INTERLEUKIN 3; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACYLATION; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG CONFORMATION; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; FRAGMENT BASED DRUG DESIGN; HINGE REGION; HYDROGENATION; IC50; MOLECULAR SIZE; NITRATION; NUCLEOPHILICITY; PRIORITY JOURNAL;

EID: 84920719081     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5001245     Document Type: Article

References (34)

1. Gil, M.; Yang, Y.; Lee, Y.; Choi, I.; Ha, H. Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells Gene 1997, 195, 295-301
2. Egan, B.; Zierath, J. R. Hunting for the SNARK in metabolic disease Am. J. Physiol. Endocrinol. Metab. 2009, 296, E969-E972
3. Lizcano, J. M.; Goransson, O.; Toth, R.; Deak, M.; Morrice, N. A.; Boudeau, J.; Hawley, S. A.; Udd, L.; Makela, T. P.; Hardie, D. G.; Alessi, D. R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1 EMBO J. 2004, 23, 833-843
4. Gray, D.; Jubb, A. M.; Hogue, D.; Dowd, P.; Kljavin, N.; Yi, S.; Bai, W.; Frantz, G.; Zhang, Z.; Koeppen, H.; de Sauvage, F. J.; Davis, D. P. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers Cancer Res. 2005, 65, 9751-9761
5. Nakano, I.; Masterman-Smith, M.; Saigusa, K.; Paucar, A. A.; Horvath, S.; Shoemaker, L.; Watanabe, M.; Negro, A.; Bajpai, R.; Howes, A.; Lelievre, V.; Waschek, J. A.; Lazareff, J. A.; Freije, W. A.; Liau, L. M.; Gilbertson, R. J.; Cloughesy, T. F.; Geschwind, D. H.; Nelson, S. F.; Mischel, P. S.; Terskikh, A. V.; Kornblum, H. I. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells J. Neurosci. Res. 2008, 86, 48-60
6. Pickard, M. R.; Green, A. R.; Ellis, I. O.; Caldas, C.; Hedge, V. L.; Mourtada-Maarabouni, M.; Williams, G. T. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer Breast Cancer Res. 2009, 11, R60
7. Lin, M.-L.; Park, J.-H.; Toshihiko Nishidate, T.; Nakamura, Y.; Katagiri, T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family Breast Cancer Res. 2009, 11, R17
8. Kuner, R.; Fälth, M.; Pressinotti, N. C.; Brase, J. C.; Puig, S. B.; Metzger, J.; Gade, S.; Schäfer, G.; Bartsch, G.; Steiner, E.; Klocker, H.; Sültmann, H. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer J. Mol. Med. 2013, 91, 237-248
9. Ryu, B.; Kim, D. S.; DeLuca, A. M.; Alani, R. M. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression PLoS One 2007, 2, e594
10. Ku, J.-L.; Shin, Y.-K.; Kim, D.-W.; Kim, K.-H.; Choi, J.-S.; Hong, S.-H.; Jeon, Y.-K.; Kim, S.-H.; Kim, H.-S.; Park, J.-H.; Kim, I.-J.; Park, J.-G. Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers Carcinogenesis 2010, 31, 1003-1009
11. Joshi, K.; Banasavadi-Siddegowa, Y.; Mo, X.; Kim, S.-H.; Mao, P.; Kig, C.; Nardini, D.; Sobol, R. W.; Chow, L. M. L.; Kornblum, H. I.; Waclaw, R.; Beullens, M.; Nakano, I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells Stem Cells 2013, 31, 1051-1063
12. Gu, C.; Banasavadi-Siddegowda, Y. K.; Joshi, K.; Nakamura, Y.; Kurt, H.; Gupta, S.; Nakano, I. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner Stem Cells 2013, 31, 870-881
13. Hebbard, L. W.; Maurer, J.; Miller, A.; Lesperance, J.; Hassell, J.; Oshima, R. G.; Terskikh, A. V. Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo Cancer Res. 2010, 70, 8863-8873
14. Chung, S.; Suzuki, H.; Miyamoto, T.; Takamatsu, N.; Tatsuguchi, A.; Ueda, K.; Kijima, K.; Nakamura, Y.; Matsuo, Y. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer Oncotarget 2012, 3, 1629-1640
15. Beullens, M.; Vancauwenbergh, S.; Morrice, N.; Derua, R.; Ceulemans, H.; Waelkens, E.; Bollen, M. Substrate specificity and activity regulation of protein kinase MELK J. Biol. Chem. 2005, 280, 40003-40011
16. Kig, C.; Beullens, M.; Beke, L.; Van Eynde, A.; Linders, J. T. M.; Brehmer, D.; Bollen, M. Maternal embryonic leucine-zipper kinase (MELK) reduces replication stress in glioblastoma cells J. Biol. Chem. 2013, 288, 24223-24233
17. Bain, J.; Plater, L.; Elliott, M.; Shapiro, N.; Hastie, C. J.; Mclaughlan, H.; Klevernic, I.; Arthur, J. S. C.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007, 408, 297-315
18. Fraley, M. E.; Rubino, R. S.; Hoffman, W. F.; Hambaugh, S. R. Optimization of a pyrazolo[1,5- a ]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics Bioorg. Med. Chem. Lett. 2002, 12, 3537-3541
19. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 2001, 108, 1167-1174
20. Handa, N.; Takagi, T.; Saijo, S.; Kishishita, S.; Takaya, D.; Toyama, M.; Terada, T.; Shirouzu, M.; Suzuki, A.; Lee, S.; Yamauchi, T.; Okada-Iwabu, M.; Iwabu, M.; Kadowaki, T.; Minokoshi, Y.; Yokoyama, S. Structural basis for compound C inhibition of the human AMP-activated protein kinase [alpha]2 subunit kinase domain Acta Crystallogr. 2011, D67, 480-487
21. Matsuo, Y.; Hisada, S.; Nakamura, Y.; Ahamed, F.; Huntley, R.; Walker, J. R.; Decornez, H. Quinoline derivatives and melk inhibitors containing the same. WO 2012016082.
22. Matsuo, Y.; Hisada, S.; Nakamura, Y.; Ahmed, F.; Walker, J. R.; Huntley, R. 1,5-Naphthyridine derivatives and melk inhibitors containing the same. WO 2013109388.
23. Mahasenan, K. V.; Li, C. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example J. Chem. Inf. Model. 2012, 52, 1345-1355
24. Kowalczyk, P.; Wegryn, P.; Edyta, P.; Zarebski, A.; Sabiniarz, A.; Stefanska, K.; Kwiek, U.; Zawadzki, P.; Krawczynska, K.; Zurawska, M.; Trebacz, A.; Prymula, K.; Milik, M.; Brzozka, K. Development of selective MELK kinase inhibitors for cancer treatments. AACR 2013, poster 2160.
25. Canevari, G.; Re Depaolini, S.; Cucchi, U.; Bertrand, J. A.; Casale, E.; Perrera, C.; Forte, B.; Carpinelli, P.; Felder, E. R. Structural insight into materal embryonic leucine zipper kinase (MELK) conformation and inhibition towards structure-based drug design Biochemistry 2013, 52, 6380-6387
26. Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: the first drug approved for BRAF-mutant cancer Nat. Rev. Drug Discovery 2012, 11, 873-886
27. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192
28. Cao, L.-S.; Wang, J.; Chen, Y.; Deng, H.; Wang, Z.-X.; Wu, J.-W. Structural basis for the regulation of maternal embryonic leucine zipper kinase PLoS One 2013, 8, e70031
29. 50)/HAC. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
30. Kerkela, R.; Woulfe, K. C.; Durand, J.-B.; Vagnozzi, R.; David Kramer, D.; Chu, T. F.; Beahm, C.; Chen, M. H.; Force, T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase Clin. Transl. Sci. 2009, 2, 15-25
31. Angell, R. M.; Bamborough, P.; Cleasby, A.; Cockerill, S. G.; Jones, K. L.; Mooney, C. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38a kinase inhibitors 1: discovery and binding mode Bioorg. Med. Chem. Lett. 2008, 18, 318-323
32. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. D. Identification of inhibitors of protein kinase B using fragment-based lead discovery J. Med. Chem. 2007, 50, 2293-2296
33. Schärfer, C.; Schulz-Gasch, T.; Ehrlich, H.-C.; Guba, W.; Rarey, M.; Stahl, M. Torsion angle preferences in druglike chemical space: a comprehensive guide J. Med. Chem. 2013, 56, 2016-2028
34. Warmuth, M.; Kim, S.; Gu, X.-J.; Xia, G.; Adrián, F. Ba/F3 cells and their use in kinase drug discovery Curr. Opin. Oncol. 2007, 19, 55-60